Download PDFPDF
Post BNT162b2 mRNA COVID-19 vaccination Henoch-Schӧnlein Pupura
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Other examples of COVID-19-related vasculitis

    oscar,m jolobe, retired geriatrician, British Medical Association
    April 03, 2022
    The occurrence of Henoch-Schonlein purpura after vaccination against COVID-19 infection(1) is, to a certain extent, predictable, given the fact that other subtypes of vasculitis have been reported after vaccination against this pathogen(2)(3). In one instance the temporal artery was involved, and the histological findings comprised infiltration with multinucleated giant cells, histiocytes, lymphocytes, and eosinophils. The patient had presented with bilateral headache, fever, fatigue, and myalgia, 2 days after receiving the second dose of a COVID-mRNA vaccine(2). In the second example granulomatous vasculitis involving the kidney occurred after administration of the AstraZeneca vaccine(3).
    Even on its own, without the mediation of a vaccine, COVID-19 infection can trigger the occurrence of vasculitis(4). In the latter example a 71 year old woman presented with cough, fever, malaise and a pruritic rash on both legs, 2 weeks after her husband had been hospitalised for COVID-19 infection. The rash consisted of purpuric macules and papules , extending from ankles to the thighs. Histology revealed small-vessel vasculitis characterised by fibrinoid necrosis and infiltration by neutrophils.. Direct immunofluorescence revealed granular deposition of C3 within vessel walls. A nasopharyngeal swab was positive for COVID-19, using the reverse transcriptase polymerase chain reaction test(...

    Show More
    Conflict of Interest:
    None declared.